eledon pharmaceuticals, inc. is a clinical stage biotechnology company using its expertise in targeting the cd40l pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. our lead program, at-1501, is a potential best-in-class humanized igg1 anti-cd40l antibody with high affinity for cd40l, a well-validated biological target with broad therapeutic potential. the cd40/cd40l pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
Company profile
Ticker
ELDN
Exchange
Website
CEO
Gregory Flesher
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
SEC CIK
Corporate docs
Subsidiaries
Otic Pharma, Ltd. ...
ELDN stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Mar 24
8-K
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
9 Nov 23
8-K
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
2 Nov 23
8-K
Departure of Directors or Certain Officers
2 Oct 23
8-K
Departure of Directors or Certain Officers
20 Sep 23
8-K
Departure of Directors or Certain Officers
13 Sep 23
S-8
Registration of securities for employees
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Transcripts
ELDN
Earnings call transcript
2023 Q1
11 May 23
ELDN
Earnings call transcript
2022 Q4
30 Mar 23
ELDN
Earnings call transcript
2022 Q3
15 Nov 22
ELDN
Earnings call transcript
2022 Q2
12 Aug 22
ELDN
Earnings call transcript
2022 Q1
13 May 22
ELDN
Earnings call transcript
2021 Q4
25 Mar 22
ELDN
Earnings call transcript
2021 Q3
12 Nov 21
ELDN
Earnings call transcript
2021 Q2
13 Aug 21
ELDN
Earnings call transcript
2021 Q1
14 May 21
ELDN
Earnings call transcript
2020 Q4
30 Mar 21
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
4
James A. Jr. Robinson
3 Oct 23
4
Allan Kirk
3 Oct 23
3
James A. Jr. Robinson
2 Oct 23
3
Allan Kirk
2 Oct 23
4
MARK N LAMPERT
9 May 23
4
Bryan E. Smith
2 May 23
4
Steven Perrin
2 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.67 mm | 3.67 mm | 3.67 mm | 3.67 mm | 3.67 mm | 3.67 mm |
Cash burn (monthly) | 12.43 mm | 5.19 mm | 3.73 mm | 7.61 mm | 4.08 mm | 3.32 mm |
Cash used (since last report) | 85.25 mm | 35.57 mm | 25.61 mm | 52.22 mm | 28.02 mm | 22.80 mm |
Cash remaining | -81.58 mm | -31.90 mm | -21.94 mm | -48.56 mm | -24.35 mm | -19.13 mm |
Runway (months of cash) | -6.6 | -6.2 | -5.9 | -6.4 | -6.0 | -5.8 |
Institutional ownership, Q2 2023
46.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 7 |
Closed positions | 4 |
Increased positions | 8 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 12.20 bn |
Total shares | 11.60 mm |
Total puts | 4.60 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
BVF | 4.33 mm | $5.93 bn |
Biotechnology Value Fund L P | 2.33 mm | $9.31 mm |
Armistice Capital | 1.84 mm | $2.52 bn |
Vanguard | 679.56 k | $930.99 mm |
Woodline Partners | 516.68 k | $707.85 mm |
Ensign Peak Advisors | 443.00 k | $606.91 mm |
RY Royal Bank Of Canada | 273.35 k | $374.00 mm |
CM Management | 234.80 k | $322.00 k |
Ikarian Capital | 221.83 k | $303.91 mm |
Geode Capital Management | 169.65 k | $232.42 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Oct 23 | Allan Kirk | Stock Option Common Stock | Grant | Acquire A | No | No | 1.55 | 150,437 | 233.18 k | 150,437 |
2 Oct 23 | Robinson James A. Jr. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.55 | 150,437 | 233.18 k | 150,437 |
5 May 23 | Partners L P/il BVF | Common Stock, $0.001 par value | Buy | Acquire P | No | No | 0 | 86,341 | 0.00 | 145,029 |
5 May 23 | Partners L P/il BVF | Common Stock, $0.001 par value | Buy | Acquire P | No | No | 0 | 837,146 | 0.00 | 1,812,558 |
5 May 23 | Partners L P/il BVF | Common Stock, $0.001 par value | Buy | Acquire P | No | No | 0 | 1,055,445 | 0.00 | 2,330,418 |
5 May 23 | Partners L P/il BVF | Warrants to Purchase Common Stock Common Stock, $0.001 par value | Buy | Acquire P | No | No | 3 | 252,291 | 756.87 k | 252,291 |
5 May 23 | Partners L P/il BVF | Warrants to Purchase Common Stock Common Stock, $0.001 par value | Buy | Acquire P | No | No | 3 | 2,446,209 | 7.34 mm | 2,446,209 |
5 May 23 | Partners L P/il BVF | Warrants to Purchase Common Stock Common Stock, $0.001 par value | Buy | Acquire P | No | No | 3 | 3,084,090 | 9.25 mm | 3,084,090 |
5 May 23 | Partners L P/il BVF | Pre-funded Warrants to Purchase Common Stock Common Stock, $0.001 par value | Buy | Acquire P | No | No | 0.001 | 165,950 | 165.95 | 165,950 |
5 May 23 | Partners L P/il BVF | Pre-funded Warrants to Purchase Common Stock Common Stock, $0.001 par value | Buy | Acquire P | No | No | 0.001 | 1,609,063 | 1.61 k | 1,609,063 |
News
HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $13 Price Target
22 Mar 24
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
21 Mar 24
Eledon Pharmaceuticals Announces Use Of Tegoprubart In First-Ever Transplant Of Genetically Modified Kidney From A Pig To A Human
21 Mar 24